Pharmaindustrie
Study in rats finds long-term omeprazole use disrupts mineral levels linked to anemia and bone health risks
Von KI berichtet Bild generiert von KI Fakten geprüft
Researchers in Brazil report that prolonged use of the proton pump inhibitor (PPI) omeprazole altered iron and calcium measures in adult rats and shifted how several minerals were distributed across organs—changes they say are consistent with higher risks of anemia and possible bone health harms. The authors and Brazil’s health regulator stress that PPIs remain effective for acid-related disorders, but warn against extended, unsupervised use.
Collegium Pharmaceutical, Inc. (COLL) held an investor conference call on March 19, 2026, to discuss its acquisition of AZSTARYS and relevant corporate subsidiaries from Corium Therapeutics. The deal aims to expand the company's position in the ADHD market. Executives including CEO Vikram Karnani joined the call.
Von KI berichtet
Relmada Therapeutics, Inc. (RLMD) conducted its fourth quarter and full-year 2025 earnings conference call on March 19, 2026, at 4:30 PM EDT. The company released a press release detailing its business update and financial results for the periods ended December 31, 2025. Management highlighted forward-looking statements with associated risks.
Alkermes plc has published a slide deck accompanying its 2025 fourth-quarter earnings call. The materials were made available on February 25, 2026. This release provides insights into the company's financial performance for the period.
Von KI berichtet
Sarepta Therapeutics, Inc. conducted its fourth quarter 2025 earnings call on February 25, 2026. The company released its financial results earlier that day, with details available on its website. Executives including CEO Douglas Ingram participated in the discussion.
Ägyptens Gesundheits- und Bevölkerungsminister Khaled Abdel Ghaffar traf sich mit Kasachstans Botschafter in Ägypten, Askar Zhenis, um die bilaterale Kooperation im Gesundheitswesen und bei pharmazeutischen Fertigungstechnologien zu stärken. Abdel Ghaffar betonte Ägyptens Interesse an der Ausweitung der Beziehungen durch Transfer pharmazeutischer Fertigungstechnologien und Angleichung der Good-Manufacturing-Practice-Standards. Die Gespräche umfassten die Zusammenarbeit bei pharmazeutischer Produktion, Biotechnologie und öffentlichen Gesundheitsinitiativen.
Von KI berichtet
Chinese biotech firm SciNeuro Pharmaceuticals has partnered with Swiss pharmaceutical giant Novartis in a deal worth nearly $1.7 billion to develop treatments for Alzheimer's disease, which affects some 55 million people worldwide. The agreement grants Novartis exclusive worldwide rights to develop and commercialise SciNeuro's antibody candidates for the progressive brain disease. SciNeuro's novel amyloid beta-targeted antibody programme leverages proprietary blood-brain barrier shuttle technology to help more of the drug cross into the brain where Alzheimer's damage occurs.
Ägypten intensiviert Forschungszusammenarbeit mit Takeda
Dienstag, 10. März 2026, 18:13 UhrRoche shares decline after giredestrant trial fails endpoint
Donnerstag, 05. März 2026, 02:11 UhrClara Foods develops world's first animal-free pepsin
Montag, 02. März 2026, 08:51 UhrÄgypten enthüllt integrierten Plan zur Förderung pharmazeutischer und Bekleidungsexporte
Sonntag, 01. März 2026, 03:28 UhrCollegium Pharmaceutical publishes Q4 2025 earnings presentation
Dienstag, 17. Februar 2026, 01:32 UhrFarmacias Similares beginnt Expansion nach Japan
Samstag, 14. Februar 2026, 10:20 UhrÄgypten bietet WHO-zertifizierte Expertise zur Stärkung der Medikamentenproduktion in Afrika an
Donnerstag, 05. Februar 2026, 16:06 UhrJapanese drugmakers slump after Trump unveils discount drug website
Freitag, 30. Januar 2026, 21:57 UhrAustralian sepsis drug advances in human trial
Samstag, 17. Januar 2026, 13:01 UhrDelhi-Hochgericht erlaubt günstigeres Krebsmedikament in Indien